American Association for Cancer Research

Table 3

Effect of serum TIMP and ICTP on 1-year (1-y) and 5-year (5-y) survival (%) in lung cancer patients (n = 141) according to different histopathological diagnoses or stages

	TIMP1 ≤ 300 ng/ml	TIMP-1 > 300 ng/ml	ICTP ≤ 5 μg/liter	ICTP > 5 μg/liter	ICTP ≤ 5 μg/liter and TIMP1 ≤ 300 ng/ml	ICTP > 5 μg/liter and TIMP-1 > 300 ng/ml
Squamous cell carcinoma
n	26	33	47	12	24	10
1-y	79	61	67	54	81	64^a
5-y	47	45	42	45	44	51
Adenocarcinoma
n	18	20	29	9	16	7
1-y	79	44^a	63	22	65	14^a
5-y	27	31	39	22	28	14
Small cell carcinoma
n	5	6	10	1	5	1
1-y	53	44	54	0	53	0
5-y	53	44	54	0
Stage I
n	19	15	33	7	13	4
1-y	83	83	84	80	82	75
5-y	58	53	80	52	51	75
Stage II
n	11	5	11	9	4	6
1-y	90	75	89	83	75	83
5-y	75	56	63	62	75	62
Stage IIIA
n	20	14	34	10	16	4
1-y	73	30^a	60	42	73	0
5-y	17	20	42	26	17	0
Stage IIIB
n	11	19	38	22	10	7
1-y	38	8	28	0^a	42	0
5-y	25	8	28	0	28	0
All
n	71	76	102	31	54	24
1-y	67	48	64	42^a	69	38
5-y	40	32	39	37	40	33

	TIMP1 ≤ 300 ng/ml	TIMP-1 > 300 ng/ml	ICTP ≤ 5 μg/liter	ICTP > 5 μg/liter	ICTP ≤ 5 μg/liter and TIMP1 ≤ 300 ng/ml	ICTP > 5 μg/liter and TIMP-1 > 300 ng/ml
Squamous cell carcinoma
n	26	33	47	12	24	10
1-y	79	61	67	54	81	64^a
5-y	47	45	42	45	44	51
Adenocarcinoma
n	18	20	29	9	16	7
1-y	79	44^a	63	22	65	14^a
5-y	27	31	39	22	28	14
Small cell carcinoma
n	5	6	10	1	5	1
1-y	53	44	54	0	53	0
5-y	53	44	54	0
Stage I
n	19	15	33	7	13	4
1-y	83	83	84	80	82	75
5-y	58	53	80	52	51	75
Stage II
n	11	5	11	9	4	6
1-y	90	75	89	83	75	83
5-y	75	56	63	62	75	62
Stage IIIA
n	20	14	34	10	16	4
1-y	73	30^a	60	42	73	0
5-y	17	20	42	26	17	0
Stage IIIB
n	11	19	38	22	10	7
1-y	38	8	28	0^a	42	0
5-y	25	8	28	0	28	0
All
n	71	76	102	31	54	24
1-y	67	48	64	42^a	69	38
5-y	40	32	39	37	40	33

P < 0.05.

View Large

This Feature Is Available To Subscribers Only